Mowery & Schoenfeld Wealth Management LLC Has $246,000 Position in AstraZeneca PLC $AZN

Key Points

• Mowery & Schoenfeld Wealth Management LLC significantly reduced its holdings in AstraZeneca PLC by 73.8% during the second quarter, leaving them with a position valued at $246,000.
• Several institutional investors have recently increased their stakes in AstraZeneca, with Larson Financial Group growing its position by 297.9% in the first quarter.
• AstraZeneca's stock has a consensus rating of "Moderate Buy" from analysts, with a current target price of $86.00.

Mowery & Schoenfeld Wealth Management LLC lowered its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 73.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,521 shares of the company's stock after selling 9,936 shares during the quarter. Mowery & Schoenfeld Wealth Management LLC's holdings in AstraZeneca were worth $246,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC increased its position in AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company's stock valued at $28,000 after purchasing an additional 289 shares during the period. Richardson Financial Services Inc. grew its position in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company's stock worth $28,000 after buying an additional 149 shares during the period. FNY Investment Advisers LLC acquired a new stake in shares of AstraZeneca during the 1st quarter worth approximately $29,000. Costello Asset Management INC acquired a new stake in shares of AstraZeneca during the 1st quarter worth approximately $29,000. Finally, Highline Wealth Partners LLC grew its position in shares of AstraZeneca by 447.4% during the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock worth $31,000 after buying an additional 340 shares during the period. Institutional investors and hedge funds own 20.35% of the company's stock.

Analyst Upgrades and Downgrades

AZN has been the subject of several research reports. Weiss Ratings reissued a "buy (b)" rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Berenberg Bank set a $97.00 price objective on AstraZeneca in a research note on Wednesday, July 9th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $86.00.

AstraZeneca Stock Down 0.0%

AZN stock opened at $84.51 on Tuesday. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $262.10 billion, a PE ratio of 31.77, a PEG ratio of 1.55 and a beta of 0.36. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $86.57. The stock has a 50-day simple moving average of $79.38 and a two-hundred day simple moving average of $73.54.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting analysts' consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.08 billion. During the same quarter in the previous year, the firm earned $1.24 EPS. The company's quarterly revenue was up 16.1% compared to the same quarter last year. On average, equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were given a $0.505 dividend. The ex-dividend date was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca's payout ratio is presently 37.97%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.